AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 222 min read$AYTU

AYTU BIOPHARMA, INC (AYTU): Results of Operations and Financial Condition

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 mi

Original reporting
SEC EDGAR 8-K
Published Sep 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AYTU
Neutral
medium confidence
Mentioned
$AYTU
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AYTUNeutralMed
01

Why it matters

The release provides the first public numbers for the EXXUA launch and overall financial health, informing valuation and short‑term trading decisions.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking CNS drug launches and small‑cap earnings beats.

03

What to watch

Cash runway of $26.3 M and upcoming payer negotiations could materially affect future performance.

Relevance 7/10Novelty 8/10Timing: post‑market Sep 22 2026

Background

AYTU BioPharma filed an 8‑K Item 2.02 disclosing its FY2026 and Q4 operational and financial results.

Company-level read

Ticker impact

$AYTUNeutralMedium confidence
Context

SEC 8‑K reports FY2026 and Q4 results with net revenue, adjusted EBITDA and cash balance figures.

Expected impact

Potential modest upside on positive guidance; downside risk if guidance remains weak.

Evidence & confidence

Results are primary disclosure but small scale; market may price in incremental improvement.

Market effects

Sector

Highlights growth trajectory for CNS specialty pharma and EXXUA launch within the MDD market.

Regional

US‑focused; limited broader regional effect.

Global

Minimal global impact beyond niche CNS sector.

Counterpoint

What could challenge this read

Revenue decline year‑over‑year and negative adjusted EBITDA suggest the stock may face pressure despite launch momentum.

Key entities

  • Executive
    Josh Disbrow

    Chief Executive Officer of AYTU providing commentary on results.

Read at source← All news

Related articles

SEP 22
$AZOMedAI 8/10

AutoZone Q4 EPS Hits $56.05 as Annual Sales Reach $20.3bn

AutoZone (AZO) reported Q4 2026 EPS of $56.05, up from $48.71 a year earlier, with net sales of $6.6bn, a 5.6% increase. Full-year sales reached $20.3bn, up 7.4%. Gross margin rose to 53.3%, boosted by tariff refunds and LIFO benefits. The company opened 175 new stores, ending the year with 8,031 locations. Shares rose 4.33% post-earnings.

financial-news.co.uk2 min
SEP 22
$AZOHighAI 8/10

Why AutoZone (AZO) Stock Is Trading Up Today

AutoZone (AZO) shares rose 6.1% after reporting Q4 EPS of $56.05, beating estimates. Net sales were $6.6B, missing expectations. Same-store sales grew 1.6%, and gross margin expanded 182 bps to 53.3%. The company's stock has had limited volatility, with today's move being notable. AZO is down 9.9% YTD, trading 30.6% below its 52-week high.

financialcontent.com2 min
SEP 22
$AMGNMedAI 8/10

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data - Amgen (NA

Amgen (AMGN) reported positive results from its Phase 3 OASIZ 301 trial for dazodalibep in treating Sjögren’s disease, meeting the primary endpoint. The study showed statistically significant improvements in disease activity scores. Adverse events were low and similar to placebo. Amgen plans to share full data at a future conference and awaits results from another trial, OASIZ 303, for potential FDA filing. Shares rose 3.54% to $407.08. Analysts expect two positive trials for approval.

benzinga.com4 min
SEP 22
$MLKNHighAI 8/10

MillerKnoll, Inc. Q1 2027 Earnings Call Summary

MillerKnoll reported a 3.4% revenue decline in Q1 2027 due to soft North American demand, offset by international growth. The company lowered full-year sales guidance to $3.88B-$4.03B but maintained EPS outlook. Management cited tariffs, inflation, and election uncertainty as challenges, while focusing on cost management and debt reduction. Orders improved in September, showing growth across all segments.

yahoo.com3 min